News

Gloucester has presented preclinical data, which demonstrates that the combination of Istodax (Romidepsin) and Velcade (Bortezomib) resulted in synergistic anti-tumor activity in B-cell non-Hodgkin’s lymphoma cell lines. Istodax

The FDA has approved Lilly’s Zyprexa (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder

Allos Therapeutics (Allos) has entered into a collaborative agreement with Idis, to manage the named patient program for Folotyn (pralatrexate injection) outside of the US. The FDA has

Watson Pharmaceuticals (Watson) has confirmed that its subsidiary, Watson Laboratories has filed an Abbreviated New Drug Application (ANDA) with the FDA seeking approval to market its 8mg Ramelteon

The FDA has approved once-daily AstraZeneca’s Seroquel XR (quetiapine fumarate) extended release tablets as adjunctive treatment to antidepressants in adults with major depressive disorder (MDD). In addition to

Gwalia Packaging Group has received a contract to supplychild resistant containers and closers for multi-vitamins, reported packagingnews. Earlier in March 2008, the company had announced an investment programme,

Absorption Systems has introduced a renovated surgical suite for preclinical medical device testing at the company’s facility in San Diego, CA. The company’s AAALAC accredited, GLP-compliant facility is

Stentys has reported the first patient enrollment in the Apposition II clinical study, a randomised trial comparing the Stentys self-expanding stent with a balloon-expandable stent in AMI patients.

Oxygen Biotherapeutics (Oxygen) has reported the enrollment of first patient in the Phase II-b, dose escalation, clinical trial in Switzerland for use of Oxycyte emulsion in traumatic brain